
Sarepta Therapeutics SRPT
$ 16.96
-0.93%
Quarterly report 2026-Q1
added 05-06-2026
Sarepta Therapeutics DIO Ratio 2011-2026 | SRPT
Annual DIO Ratio Sarepta Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 1980 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11.9 K | - | - | - | - | - | 1.11 K | 1.34 K | 4.15 K | 36 K | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 36 K | 1.11 K | 10.9 K |
DIO Ratio of other stocks in the Biotechnology industry
| Issuer | DIO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
FSD Pharma
HUGE
|
174 | - | 5743.5 % | $ 69.7 M | ||
|
Happiness Biotech Group Limited
HAPP
|
1.91 K | - | 1.35 % | $ 17.8 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
512 | - | - | $ 40.3 B | ||
|
AstraZeneca PLC
AZN
|
206 | - | - | $ 96.9 B | ||
|
Midatech Pharma plc
MTP
|
40.6 | - | -18.52 % | $ 27.3 M | ||
|
Esperion Therapeutics
ESPR
|
2.46 K | $ 3.13 | - | $ 651 M | ||
|
Eton Pharmaceuticals
ETON
|
150 | $ 35.0 | 1.6 % | $ 942 M | ||
|
Институт стволовых клеток человека
ISKJ
|
275 | - | - | - | ||
|
Berkeley Lights
BLI
|
246 | - | -7.31 % | $ 87 M | ||
|
Autolus Therapeutics plc
AUTL
|
70.7 | $ 1.65 | 1.85 % | $ 439 M | ||
|
Grifols, S.A.
GRFS
|
0.000171 | $ 8.11 | -0.98 % | $ 5.51 B | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
185 | - | -4.36 % | $ 27 M | ||
|
Heron Therapeutics
HRTX
|
644 | $ 0.87 | 3.09 % | $ 145 M | ||
|
Anika Therapeutics
ANIK
|
159 | $ 15.02 | -0.79 % | $ 215 M | ||
|
Aeterna Zentaris
AEZS
|
55.6 | - | 5.93 % | $ 314 M | ||
|
Incyte Corporation
INCY
|
78.4 | $ 97.41 | 0.34 % | $ 19 B | ||
|
Ionis Pharmaceuticals
IONS
|
259 | $ 75.78 | 0.96 % | $ 12.1 B | ||
|
Coherus BioSciences
CHRS
|
97.5 | $ 1.57 | 3.97 % | $ 184 M | ||
|
Albireo Pharma
ALBO
|
26.1 | - | -0.23 % | $ 916 M | ||
|
Arcutis Biotherapeutics
ARQT
|
185 | $ 21.01 | 2.64 % | $ 2.67 B |